Last edition
News about "Skyrizi Phase 3 AFFIRM study"
AbbVie Reports Phase 3 Skyrizi Data for Crohn's Disease
AbbVie has presented new phase 3 AFFIRM data showing clinical and endoscopic outcomes with subcutaneous SKYRIZI (risankizumab-rzaa) in patients Crohn's Disease.
Skyrizi Phase 3 AFFIRM Study | 14/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members